American Academy of Allergy, Asthma, and Immunology Annual Meeting (AAAAI 2024)

Washington, DC, US 23 February 2024 - 26 February 2024

Asthma control better with dupilumab-ICS combo

09 Apr 2024 by

Adding the anti-interleukin-4 receptor alpha monoclonal antibody dupilumab to an inhaled corticosteroid (ICS) reduces asthma exacerbations and improves lung function in a post hoc analysis of the LIBERTY ASTHMA QUEST trial.

Asthma control better with dupilumab-ICS combo

09 Apr 2024

Dupilumab reverses gene dysregulation in EoE

24 Mar 2024 by

Treatment with dupilumab helps normalize the expression of genes dysregulated in children with active eosinophilic esophagitis (EoE), according to a study.

Dupilumab reverses gene dysregulation in EoE

24 Mar 2024

Real-world use affirms mepolizumab efficacy in chronic rhinosinusitis with nasal polyps

22 Mar 2024 by

Mepolizumab proves beneficial to adults with chronic rhinosinusitis with nasal polyps treated in routine clinical practice, especially in terms of reducing oral corticosteroid (OCS) and surgical burden, according to a study. This supports clinical data from the pivotal phase III SYNAPSE study.

Real-world use affirms mepolizumab efficacy in chronic rhinosinusitis with nasal polyps

22 Mar 2024

SARS-CoV-2 antigen detected in body 14 months after infection

19 Mar 2024 by

A substantial number of plasma samples from immunocompetent people who had SARS-CoV-2 infection more than a year ago appears to contain detectable viral antigens.

SARS-CoV-2 antigen detected in body 14 months after infection

19 Mar 2024

Dupilumab mends skin barrier in children with AD, but with caveat

19 Mar 2024 by

Use of dupilumab results in normalization of stratum corneum (SC) lipids, which is responsible for skin barrier function, in children with atopic dermatitis (AD) within 1 to 2 months of treatment, according to a study presented at AAAAI 2024.

Dupilumab mends skin barrier in children with AD, but with caveat

19 Mar 2024

Garadacimab, berotralstat reduce attacks in hereditary angioedema

18 Mar 2024 by

Patients who are suffering from hereditary angioedema (HAE) may find comfort by using drugs that have been recently shown to ease HAE attacks. Treatment with either garadacimab or berotralstat results in reduced attack rates, according to studies presented at AAAAI 2024.

Garadacimab, berotralstat reduce attacks in hereditary angioedema

18 Mar 2024

Tapinarof cream effective regardless of AD severity, age in two trials

15 Mar 2024 by

Once-daily application of tapinarof cream 1% significantly improves the Eczema Area Severity Index (EASI) score in patients with atopic dermatitis (AD), regardless of their disease severity or age, according to the pivotal phase III ADORING 1 and 2 trials presented at AAAAI 2024.

Tapinarof cream effective regardless of AD severity, age in two trials

15 Mar 2024

TRuE-AD3: Ruxolitinib cream effective in children with AD

11 Mar 2024 by

Ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, appears to be effective for mild-to-moderate atopic dermatitis (AD) in children aged 2–11 years, according to the TRuE-AD3 trial presented at AAAAI 2024.

TRuE-AD3: Ruxolitinib cream effective in children with AD

11 Mar 2024

Sebetralstat fares well as oral therapy for HAE

08 Mar 2024 by

In the phase III KONFIDENT trial, oral sebetralstat provides rapid symptom relief, cuts treatment burden, and facilitates early treatment in individuals with hereditary angioedema (HAE) attacks.

Sebetralstat fares well as oral therapy for HAE

08 Mar 2024

Needle-free epinephrine an alternative for anaphylaxis?

07 Mar 2024 by

In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen^® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.

Needle-free epinephrine an alternative for anaphylaxis?

07 Mar 2024